Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Labcorp Holdings (NYSE:LH) Introduces FDA-Approved Self-Collection Tests For HPV And STIs

2025-04-01
Labcorp Holdings (NYSE:LH) saw its stock price increase by 1.49% over the last quarter, possibly driven by the announcement of its FDA-approved HPV self-collection solution and STI testing option aimed at improving women's health screening. These innovations might have boosted investor confidence despite the broader market's decline and uncertainties surrounding new tariffs impacting overall economic sentiment. The company's Q4 2024 financial results, showing improved net income and EPS,...

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

2025-04-01
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer. Labcorp will also offer a vaginal swab self-collect option for sexually transmitted infection (STI) testing. Both solutions are available by physician order and can be completed pr

Labcorp to Announce First Quarter Financial Results on April 29, 2025

2025-03-31
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Labcorp Holdings Inc. stock outperforms competitors on strong trading day

2025-03-31
Labcorp Holdings Inc. stock outperforms competitors on strong trading day

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack

2025-03-27
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.

Labcorp to close Los Angeles site, lay off 73 people

2025-03-24
Labcorp lists the plant as part of its consumer genetics business and plans to begin eliminating positions in May.

BlackRock Sustainable U.S. Value Equity Fund Q4 2024 Commentary

2025-03-20
BlackRock Sustainable U.S. Value Equity Fund posted returns of -4.18% (Institutional shares) and -4.19% (Investor A shares, without sales charge) for the fourth quarter of 2024.

Labcorp Holdings Inc. stock underperforms Thursday when compared to competitors

2025-03-20
Labcorp Holdings Inc. stock underperforms Thursday when compared to competitors

Invesco Health Care Fund Q4 2024 Commentary

2025-03-20
Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.

Why Labcorp (LH) is a Top Growth Stock for the Long-Term

2025-03-18
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.